1. Home
  2. AVRO

AVRO

AVROBIO Inc.

Logo AVROBIO Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 9:56am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Founded: 2015 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 57.0M IPO Year: 2018
Target Price: $2.00 AVG Volume (30 days): 302.9K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.27 EPS Growth: N/A
52 Week Low/High: $0.57 - $1.70 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: